Published in Pharma Law Weekly, April 5th, 2005
More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Neurodur with accompanied use protection in multiple sclerosis (MS) and other neurodegenerative diseases.
William Pursley, CepTor's chairman and CEO, stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific nerve-cell-targeted, protease-inhibiting compounds being used or developed to minimize or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly